Data access has been approved for a research study to look at the impact of British Columbia’s province-wide Smoking Cessation Program, launched in September 2011. The program provides financial assistance to cover the cost of eligible smoking cessation products.
The project is being undertaken by Greg Carney, as part of his graduate studies, and is supervised by Dr Colin Dormuth in the Department of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia.
“The evaluation will compare the effectiveness and safety of Champix, Zyban, Thrive, and Habitrol therapy for smoking cessation in the BC reimbursement program,” says Carney. “We will also examine the direct system costs associated with offering a population-based tobacco treatment program in a healthcare setting and provide monthly aggregate utilization patterns of the four smoking cessation products.”
PopData will link BC Ministry of Health, BC Vital Statistics Agency and PharmaNet data for the project.
